Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 3/20 | 0.54 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.51 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | PLAT | P00750 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.47 |
| ▸ | TUBB | P07437 | 4/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7614440 | 0.93 | TSHR (0.57) | ABCB1ABCC1MEN1KMT2AMAPT | |
| SCHEMBL7449464 | 0.89 | MEN1 (0.57) | ABCB1ABCC1MEN1KMT2AMAPT | |
| SCHEMBL7545626 | 0.88 | AKR1C3 (0.48) | ABCB1ABCC1MEN1KMT2AMAPT | |
| SCHEMBL7552310 | 0.86 | ABCB1 (0.58) | ABCB1ABCC1MEN1KMT2AMAPT | |
| SCHEMBL7991743 | 0.85 | AKR1C3 (0.50) | ABCB1ABCC1MEN1KMT2AMAPT | |
| SCHEMBL27889371 | 0.85 | TSHR (0.68) | ABCB1MEN1KMT2AMAPTPLG | |
| SCHEMBL7546319 | 0.85 | TP53 (0.56) | ABCB1ABCC1MEN1KMT2AMAPT | |
| SCHEMBL7615616 | 0.82 | PDE4B (0.56) | ABCB1ABCC1MAPTAKR1C3AKR1C2 | |
| SCHEMBL16712925 | 0.82 | ALDH1A1 (0.57) | ABCB1ABCC1MEN1KMT2AMAPT | |
| SCHEMBL7613027 | 0.82 | AKR1C3 (0.52) | ABCB1ABCC1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020028831-A1 | Phenylpyridine derivatives useful as phosphodiesterase inhibitors | MANLEY PAUL W (CH) | 2002-03-07 | — | — | US | claimed |
| CN-114478529-A | CDK inhibitor and preparation method thereof | 无锡捷化医药科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3148587-B1 | CARBONITRILE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | PFIZER (US) | 2021-02-24 | — | — | EP | disclosed |
| US-10328082-B2 | Methods of use and combinations | PFIZER INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20170252352-A1 | METHODS OF USE AND COMBINATIONS | PFIZER INC. (US) | 2017-09-07 | — | — | US | disclosed |
| CN-106572997-A | nitrile derivatives as selective androgen receptor modulators | 辉瑞公司 | 2017-04-19 | — | — | CN | disclosed |
| EP-3148587-A1 | CARBONITRILE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | Pfizer Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2925725-B1 | NOVEL SELECTIVE ANDROGEN RECEPTOR MODULATORS | PFIZER (US) | 2016-11-09 | — | — | EP | disclosed |
| CN-104854093-B | Novel selective androgen receptor modulators | 辉瑞大药厂 | 2016-10-12 | — | — | CN | disclosed |
| US-9328104-B2 | Selective androgen receptor modulators | PFIZER INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-6410547-B1 | (4-OXY-3-(ARYL)PHENYL)PYRIDINE FOR TREATMENT, PROPHYLAXIS OF INFLAMMATION, ESP. INFLAMMATORY OR OBSTRUCTIVE DISEASES OF THE AIRWAYS, E.G. FOR ASTHMA THERAPY; INHIBITORS OF PDE 4 ISOENZYME; DOWN REGULATE OR INHIBIT TNF-ALPHA RELEASE | NOVARTIS AG (CH) | 2002-06-25 | — | — | US | disclosed |
| US-20020028831-A1 | Phenylpyridine derivatives useful as phosphodiesterase inhibitors | MANLEY PAUL W (CH) | 2002-03-07 | — | — | US | disclosed |
| US-20020026061-A1 | Process for preparing 5-hydroxybenzo [b] thiophene-3-carboxylic acid derivatives | HONMA TSUNETOSHI (JP) | 2002-02-28 | — | — | US | disclosed |
| US-6346628-B1 | REACTING 4-MERCAPTOPHENOL WITH A PROPARYGL GOUP AND PROTECTION OF HYDROXYL GROUP, OXIDIZING THE PRODUCT, AND THERMAL REARRANGEMENT TO CYCLIZE, FOLLOWED BY FURTHER OXIDATION | SHIONOGI & CO., LTD. (JP) | 2002-02-12 | — | — | US | disclosed |
| US-6320060-B1 | INTRODUCING PROPARGYL GROUP INTO 4-MERCAPTOPHENOL, PROTECTING HYDROXYL GROUP, OXIDIZING COMPOUND, SUBJECTING TO THERMAL REARRANGEMENT REACTION, SUBJECTING TO STEPWISE OXIDATION OF HYDROXYMETHYL GROUP AND OPTIONALLY DEPROTECTION | SHIONOGI & CO., LTD. (JP) | 2001-11-20 | — | — | US | disclosed |
| US-6288092-B1 | BIPHENYL PYRIDINES, BENZAMIDES AND PENYLCARBOXY COMPOUNDS USED AS SELECTIVE INHIBITORS OF PHOSPHODIESTERASE 4 ISOENZYME ACTIVITY AND DOWN REGULATORS OR INHIBIT TUMOR NECROSIS FACTOR RELEASE; ANTIHISTAMINES AND ANTIINFLAMMATORY | NOVARTIS AG (CH) | 2001-09-11 | — | — | US | disclosed |
| US-6258843-B1 | DRUGS AS ENZYME INHIBITORS | NOVARTIS AG (CH) | 2001-07-10 | — | — | US | disclosed |
| US-6090817-A | Phenylpyridine derivatives useful as phosphodiesterase inhibitors | NOVARTIS AG (CH) | 2000-07-18 | — | — | US | disclosed |
| EP-0885193-A1 | TRIARYL COMPOUNDS | Novartis AG (CH) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997032853-A1 | TRIARYL COMPOUNDS | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170252352-A1 | METHODS OF USE AND COMBINATIONS | MC2R, AR, NR3C2 | ABCB1 1310/4885ABCC1 1158/4885MEN1 838/4885 |
| US-10328082-B2 | Methods of use and combinations | AR, MC2R, ESRRA | ABCB1 1203/4885ABCC1 1124/4885MEN1 820/4885 |
| US-20020028831-A1 | Phenylpyridine derivatives useful as phosphodiesterase inhibitors | PDE4A, PDE4B, PDE12 | ABCB1 518/4885ABCC1 1677/4885MEN1 4874/4885 |
| US-20020026061-A1 | Process for preparing 5-hydroxybenzo [b] thiophene-3-carboxylic acid derivatives | HPD, PTGDR2, PTGS2 | ABCB1 186/4885ABCC1 1806/4885MEN1 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.